Colombia’s health ministry and the international R&D-based pharmaceutical industry association, Afidro, are at loggerheads over legislation that gives biosimilars a faster route to market. Afidro has requested that a decree be suspended, claiming that it will lead to the approval of medicines that have not been properly tested. Meanwhile, the health ministry has accused the association of creating overly onerous barriers to competition.
The legislation in question is Decree 1782 of 2014, which seeks to establish the procedures and requirements for evaluating and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?